Core Viewpoint - The company experienced a significant decline in revenue and net profit in the first three quarters of 2025, attributed to market fluctuations and external factors such as trade wars, but showed some improvement in profit margins in Q3 [1][2]. Financial Performance - In the first three quarters of 2025, the company achieved revenue of 308 million (down 20.76% year-on-year) and a net profit of 22 million (down 75.04% year-on-year) [1]. - For Q3 2025, revenue was 105 million (down 13.84% year-on-year) with a net profit of 10 million (down 42.12% year-on-year) [1]. - The net profit margin for Q3 2025 improved to 9.21%, an increase of 6.53 percentage points from the previous quarter, mainly due to better management and R&D cost control [2]. Industry Context - The POCT (Point-of-Care Testing) industry is currently under pressure, with several companies, including competitors, experiencing revenue declines, indicating a challenging market environment [3]. - The company is launching new products, which are expected to contribute positively to revenue in the future. Notably, the heart multi-detection project has received CE marking in the EU, and the VINScreenTM series has obtained FDA approval for sale in the U.S. [3]. Strategic Initiatives - The company is strategically investing in brain-computer interface technology through its subsidiary, which could open up significant long-term market opportunities, particularly for treating severe depression [4]. - The brain-computer interface market is expected to grow, supported by policy backing and technological advancements, with the potential for accelerated commercialization of related products [4]. Profit Forecast - Revenue projections for 2025-2027 are estimated at 496 million, 693 million, and 887 million respectively, with year-on-year changes of -11.42%, +39.78%, and +28.11% [4]. - Net profit forecasts for the same period are 60 million, 158 million, and 215 million, with year-on-year changes of -64.49%, +162.50%, and +35.95% [4].